ArticleBiomolecules & biomedicine2026
Plasma p-tau217, p-tau181 and Aβ42/40 for Alzheimer's disease diagnosis: ROC accuracy and 18F-florbetapir amyloid PET-CT concordance.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis of Alzheimer's disease (AD) presents significant challenges. This study assessed the diagnostic utility of seven plasma biomarkers and PET-CT imaging in cognitively healthy individuals (HC), those with mild cognitive impairment (MCI), and AD patients. Seventy participants (20 with MCI, 35 with AD, and 15 HC) underwent plasma testing for amyloid-beta 40 (Aβ40), amyloid-beta 42 (Aβ42), the Aβ42/Aβ40 ratio, phosphorylated tau 181 (p-tau181), p-tau217, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL), along with cognitive assessments using the Mini-Mental State Examination (MMSE). Statistical comparisons among groups were performed, and receiver operating characteristic (ROC) curves were utilized to evaluate diagnostic accuracy. Spearman's correlation coefficient was applied to examine the relationships between biomarkers and MMSE scores. Additionally, 18 patients, including 14 with AD and 4 with MCI, underwent 18F-Florbetapir (18F-AV45) PET-CT amyloid imaging. The consistency between plasma biomarkers and PET-CT in detecting amyloid pathology was evaluated using Cohen's Kappa. Plasma Aβ42 levels and the Aβ42/Aβ40 ratio were significantly lower in AD patients compared to those with MCI and HC (p<0.05), while levels of p-tau181, p-tau217, NfL, and GFAP were significantly elevated (p<0.05). Aβ42 and the Aβ42/Aβ40 ratio exhibited positive correlations with MMSE scores (p<0.01), whereas p-tau181, p-tau217, GFAP, and NfL demonstrated negative correlations (p<0.001). The plasma Aβ42/Aβ40 ratio, p-tau181, and p-tau217 levels showed significant concordance with 18F-AV45 PET-CT results for detecting amyloid deposition (p<0.05). A reduced plasma Aβ42/Aβ40 ratio, along with increased p-tau181 and p-tau217 levels, is significantly associated with a clinical diagnosis of AD, cognitive decline (as indicated by lower MMSE scores), and positive amyloid deposition on PET-CT. These three core biomarkers, when combined with GFAP and NfL, may enhance diagnostic accuracy for AD in cross-sectional assessments, particularly when integrated with imaging and cognitive evaluations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.